Technological development of pharmaceutical compositions for sub-retinal fibrosis in preclinical models: implications in the consolidation of a company focused on research and innovative therapies for posterior segment eye diseases

• Grant number: 18/22323-0
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Start date: December 01, 2019
• End date: November 30, 2020
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Mariana Aparecida Brunini Rosales
• Grantee: Mariana Aparecida Brunini Rosales
• Company: R&R NovaBio Pesquisa e Desenvolvimento em Ciências Naturais Ltda
• CNAE: Pesquisa e desenvolvimento experimental em ciências físicas e naturais
• City: Campinas
• Pesquisadores principais: Franco Aparecido Rossato
• Associated research grant(s): 22/03561-2 - Technological development of pharmaceutical compositions for sub-retinal fibrosis in preclinical models. Implications in the consolidation of a company focused on research and innovative therapies for posterior segment eye diseases, AP.PIPE
• Associated scholarship(s): 19/27184-0 - Technological development of pharmaceutical compositions for sub-retinal fibrosis in preclinical models: implications in the consolidation of a company focused on research and innovative therapies for posterior segment eye diseases, BP.PIPE

Abstract

The mission of this future company in ophthalmological medicine field, will be focusing in a less explored portfolio therapies in Brazil of research and development (R&D), among them topical pharmaceutical compositions for posterior segment eye diseases associated with fibrosis, including age-related macular degeneration (AMD) in both types, responsible for central vision (retina) loss in patients over 55 years of age. Risk factors are associated with the development of the disease such as aging, heredity, hypertension, high cholesterol and smoking. Currently, the treatment options are invasive decreasing neovascularization and vascular permeability, such as anti-angiogenic intravitreal injections. The therapy has a visual acuity improvement of 40% in of patients in the first 2 years and subsequent recurrent after this period. The low efficacy may be attributed to endothelial vascular growth factor (anti-VEGF) blockade treatment does not suppresses subretinal fibrosis (disciform scar) associated with disease progression and vision loss in more than 50% of patients. The purpose of this Startup will be to develop technologies targeting this gap through a new mechanistic therapeutic view approached and proposed by the researchers involved here during the postdoctoral in the United States. It is expected that the first prototype with PIPE phase 1 will attract more investment allowing the company to progress in the next steps related to the final adjustments of technology, acquisition of ocular functional analysis equipment, scale production, patents, licensing, future clinical trials and development of future innovations. (AU)